[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed Inc. (RMD) Form 4: Director Nicole Mowad-Nassar was granted 241 restricted stock units (RSUs) on 09/02/2025. The report shows the award as a non-derivative acquisition and lists 241 shares beneficially owned following the transaction, held in a direct form. The filing explains the RSUs vest on the first anniversary of the grant date. The Form 4 was signed on behalf of Ms. Mowad-Nassar by an attorney-in-fact on 09/03/2025. No price was reported for the grant and no other transactions or derivative positions are disclosed in this filing.

Insights

Corporate Governance Expert

TL;DR: Small director equity grant aligns incentives but appears routine and not material to shareholders.

The 241 RSU award to a board director is a standard form of equity-based compensation intended to align management and director interests with shareholders. The RSUs vest on the first anniversary, which creates a short-term retention incentive. Given the modest size—241 shares with no price disclosed in the filing—the grant is unlikely to be material to ResMed's capital structure or to alter governance dynamics. This appears to be a routine director compensation action rather than a strategic change.

Securities Analyst

TL;DR: Transaction is a routine insider award with negligible direct market impact.

The Form 4 reports a non-derivative acquisition of 241 RSUs resulting in 241 shares beneficially owned directly. Absence of a cash price and the small share count suggest immateriality relative to ResMed's market capitalization. There are no dispositions or derivative positions reported, and no evidence in this filing of trading activity that would indicate liquidity or signaling effects. For investors, this filing documents compensation-related ownership but does not provide information that would likely affect valuation models.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mowad-Nassar Nicole

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	09/02/2025		A(1)		241	A	$0	241	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares awarded are restricted stock units. The RSUs vest on the first anniversary of the grant date.

	/s/ Michael Rider, attorney-in-fact for Ms. Mowad-Nassar	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nicole Mowad-Nassar report on the Form 4 for ResMed (RMD)?

The Form 4 reports a non-derivative acquisition of 241 RSUs on 09/02/2025, resulting in 241 shares beneficially owned directly.

When do the RSUs reported on the Form 4 vest?

The filing states the RSUs vest on the first anniversary of the grant date.

Was a purchase price disclosed for the RSU grant in this Form 4?

No price is reported; the transaction line shows $0 for the grant in this filing.

Did the Form 4 report any derivative securities or dispositions by the reporting person?

No. The filing discloses only a non-derivative acquisition of RSUs and does not show derivative positions or dispositions.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Michael Rider, attorney-in-fact for Ms. Mowad-Nassar on 09/03/2025.